




Name	Haeryoung Kim	
Country	Republic of Korea	
Organization	Seoul National University Hospital	
Current Position	Professor	

Educational Background

2005 – 2008	Ph.D., Pathology, Yonsei University Graduate College of Medicine
2001 – 2003	M.S., Molecular Genetics and Pathology, BK (Brain Korea) 21 Project for Medical Sciences, Yonsei University Graduate College of Medical Sciences
1994 – 2000	Medicine, Yonsei University College of Medicine

Professional Experiences

2019 – present	Professor, Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine
2017 – 2019	Associate Professor, Department of Pathology, Seoul National University Hospital
2012 – 2017	Associate Professor, Department of Pathology, Seoul National University Bundang Hospital
2012 – 2013	Visiting postdoctoral fellow, GI & Liver Pathology, Johns Hopkins Hospital, Baltimore, MD, USA (Early Pancreatic Cancer Detection Laboratory)
2008 – 2012	Assistant Professor, Department of Pathology, Seoul National University Bundang Hospital
2006 – 2008	Instructor, Department of Pathology, Seoul National University Bundang Hospital
2006	Clinical Fellow, Department of Pathology, Seoul National University Bundang Hospital
2005 – 2006	Clinical Fellow, Department of Pathology, Severance Hospital, Yonsei University
2001 – 2005	Residency, Department of Pathology, Severance Hospital, Yonsei University

Professional Organizations

Korean Society of Pathologists, Korean Society for Cytopathology, United States and Canadian Academy of Pathology, Korean Association of the Study of the Liver, Korean Liver Cancer Association, International Liver and Pancreatobiliary Pathologists Assembly in Asia

Main Scientific Publications

1. Lee Y, Lee H, Park H, Kim JW, Hwang JH, Kim J, Yoon YS, Han HS, Kim H. Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas. *Oncotarget*. 2017;8:76699-76711.
2. Park H, Lee Y, Lee H, Kim JW, Hwang JH, Kim J, Yoon YS, Han HS, Kim H. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. *Tumour Biol*. 2017;39:1010428317718403.
3. Hwang IK, Kim H, Lee YS, Kim J, Cho JY, Yoon YS, Han HS, Hwang JH. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. *Cancer Sci*. 2015 Oct;106(10):1408-13.
4. Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, Cho JY, Yoon YS, Han HS, Cha BH. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival. *Pancreas*. 2014 Apr;43(3):380-8
5. Kim H, Saka B, Knight S, Borges M, Childs E, Klein A, Wolfgang C, Herman J, Adsay VN, Hruban RH, Goggins M. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. *Clin Cancer Res*. 2014;20:1865-72.



-
6. Kim SY, Kim H, Cho JY, Lim S, Cha K, Lee KH, Kim YH, Kim JH, Yoon YS, Han HS, Kang HS. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. *Radiology*. 2014 Apr;271(1):104-12.
 7. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. *Clin Cancer Res*. 2013;19(13):3600-10
 8. Kim H, Yoo JE, Cho JY, Oh BK, Yoon YS, Han HS, Lee HS, Jang JJ, Jeong SH, Kim JW, Park YN. Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing "stemness"-related markers. *J Hepatol*. 2013;59:746-52.
 9. Lee SH, Kim H, Hwang JH, Lee HS, Cho JY, Yoon YS, Han HS. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. *Pathol Int*. 2012 Mar;62(3):167-75
 10. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN. Human hepatocellular carcinomas with "stemness"-related marker expression: keratin 19 expression and a poor prognosis. *Hepatology* 2011;54:1707-17.
 11. Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G, Park YN. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. *J Hepatol*. 2011; 54: 939-47.
-